John T. Soper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John T. Soper has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
A. Berchuck
Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina
1 shared publication- A. Catherine Casey
US Oncology, Edina Clinic, Edina, Minnesota
1 shared publication A.A. Secord
Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina
1 shared publication- Andrea Elisabeth Wahner Hendrickson
Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN
1 shared publication - Bradley Monk
Florida Cancer Specialists and Research Institute, West Palm Beach, FL, USA
1 shared publication - Casey M. Cosgrove
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH, USA
1 shared publication
Latest Publications
- 1 February 2022
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 77 (2) , 101-110
A Review of Current Management of Placental Site Trophoblastic Tumor and Epithelioid Trophoblastic Tumor
Importance: Placental site trophoblastic tumor (PSTT) and epithelioid trophoblastic tumor (ETT) are rare forms of gestational trophoblastic neoplasia (GTN). These tumors differ from choriocarcinoma as they are monophasic, have slower growth rates, have lower β-hCG concentrations, and are more chemoresistant. Placental site trophoblastic tumor and ETT can be misdiagnosed, leading to inappropriate management. Objective: The aim of this study was to review the pathogenesis, presentation, pathologic findings, and treatment for PSTT and ETT. Evidence Acquisition: A comprehensive literature review was performed identifying relevant research and review articles. Relevant textbook chapters and guidelines were also reviewed. Results: Placental site trophoblastic tumor and ETT can present months to years after any antecedent pregnancy event with abnormal uterine bleeding and an elevated β-hCG. Tumors are typically confined to the uterus and secrete lower levels of β-hCG compared with other GTNs. The International Federation of Gynecology and Obstetrics prognostic scoring system does not correlate well with prognosis. These lesions can be misdiagnosed as smooth muscle tumors, metastatic melanoma, and cervical squamous cell carcinoma. However, they can be distinguished by their unique histologic and immunophenotypic features. Conclusions: Surgery is the mainstay of treatment for early-stage PSTT and ETT. For patients with advanced disease or for those with poor prognostic indicators, such as an antecedent pregnancy interval of greater than 48 months, a multimodal treatment paradigm of surgery and chemotherapy using a high-risk GTN platinum-etoposide containing regimen is recommended. Relevance: Placental site trophoblastic tumor and ETT should be considered in the differential diagnosis in a reproductive age patient presenting with abnormal uterine bleeding and an elevated β-hCG after any antecedent pregnancy event. Target Audience: Obstetricians and gynecologists, family physicians Learning Objectives: After participating in this activity, the reader should be better able to identify the presentation and diagnosis of PSTT and ETT; explain how PSTT and ETT differ from the more common forms of GTN; and describe how surgical resection is the primary treatment modality for PSTT and ETT.
- 1 February 2022
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 77 (2) , 101-110
A Review of Current Management of Placental Site Trophoblastic Tumor and Epithelioid Trophoblastic Tumor
Importance: Placental site trophoblastic tumor (PSTT) and epithelioid trophoblastic tumor (ETT) are rare forms of gestational trophoblastic neoplasia (GTN). These tumors differ from choriocarcinoma as they are monophasic, have slower growth rates, have lower β-hCG concentrations, and are more chemoresistant. Placental site trophoblastic tumor and ETT can be misdiagnosed, leading to inappropriate management. Objective: The aim of this study was to review the pathogenesis, presentation, pathologic findings, and treatment for PSTT and ETT. Evidence Acquisition: A comprehensive literature review was performed identifying relevant research and review articles. Relevant textbook chapters and guidelines were also reviewed. Results: Placental site trophoblastic tumor and ETT can present months to years after any antecedent pregnancy event with abnormal uterine bleeding and an elevated β-hCG. Tumors are typically confined to the uterus and secrete lower levels of β-hCG compared with other GTNs. The International Federation of Gynecology and Obstetrics prognostic scoring system does not correlate well with prognosis. These lesions can be misdiagnosed as smooth muscle tumors, metastatic melanoma, and cervical squamous cell carcinoma. However, they can be distinguished by their unique histologic and immunophenotypic features. Conclusions: Surgery is the mainstay of treatment for early-stage PSTT and ETT. For patients with advanced disease or for those with poor prognostic indicators, such as an antecedent pregnancy interval of greater than 48 months, a multimodal treatment paradigm of surgery and chemotherapy using a high-risk GTN platinum-etoposide containing regimen is recommended. Relevance: Placental site trophoblastic tumor and ETT should be considered in the differential diagnosis in a reproductive age patient presenting with abnormal uterine bleeding and an elevated β-hCG after any antecedent pregnancy event. Target Audience: Obstetricians and gynecologists, family physicians Learning Objectives: After participating in this activity, the reader should be better able to identify the presentation and diagnosis of PSTT and ETT; explain how PSTT and ETT differ from the more common forms of GTN; and describe how surgical resection is the primary treatment modality for PSTT and ETT.
- 29 November 2021
- Published by Elsevier in Gynecologic Oncology
- Vol. 164 (2) , 398-405
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study
- 29 November 2021
- Published by Elsevier in Gynecologic Oncology
- Vol. 164 (2) , 398-405
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study
- Top Cited PapersOpen Access
- 5 January 2021
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 137 (2) , 355-370
Gestational Trophoblastic Disease
This review summarizes the current evaluation and management of gestational trophoblastic disease, including evacuation of hydatidiform moles, surveillance after evacuation of hydatidiform mole and the diagnosis and management of gestational trophoblastic neoplasia. Most women with gestational trophoblastic disease can be successfully managed with preservation of reproductive function. It is important to manage molar pregnancies properly to minimize acute complications and to identify gestational trophoblastic neoplasia promptly. Current International Federation of Gynecology and Obstetrics guidelines for making the diagnosis and staging of gestational trophoblastic neoplasia allow uniformity for reporting results of treatment. It is important to individualize treatment based on their risk factors, using less toxic therapy for patients with low-risk disease and aggressive multiagent therapy for patients with high-risk disease. Patients with gestational trophoblastic neoplasia should be managed in consultation with an individual experienced in the complex, multimodality treatment of these patients.
- 5 January 2021
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 137 (2) , 355-370
Top Cited PapersOpen AccessGestational Trophoblastic Disease
This review summarizes the current evaluation and management of gestational trophoblastic disease, including evacuation of hydatidiform moles, surveillance after evacuation of hydatidiform mole and the diagnosis and management of gestational trophoblastic neoplasia. Most women with gestational trophoblastic disease can be successfully managed with preservation of reproductive function. It is important to manage molar pregnancies properly to minimize acute complications and to identify gestational trophoblastic neoplasia promptly. Current International Federation of Gynecology and Obstetrics guidelines for making the diagnosis and staging of gestational trophoblastic neoplasia allow uniformity for reporting results of treatment. It is important to individualize treatment based on their risk factors, using less toxic therapy for patients with low-risk disease and aggressive multiagent therapy for patients with high-risk disease. Patients with gestational trophoblastic neoplasia should be managed in consultation with an individual experienced in the complex, multimodality treatment of these patients.
- 23 May 2010
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 15 (6) , 593-600
The Role of Surgery and Radiation Therapy in the Management of Gestational Trophoblastic Disease
Learning Objectives: After completing this course, the reader will be able to: Describe the indications for surgical intervention in the management of patients with hydatidiform moles and malignant GTN in order to choose patients most likely to benefit from these interventions.Discuss the use of radiation in the management of patients with malignant GTN and consider its use as an adjunct to chemotherapy or surgery. CME This article is available for continuing medical education credit at CME.TheOncologist.com The primary management of hydatidiform moles remains surgical evacuation followed by human chorionic gonadotropin level monitoring. Although suction dilatation and evacuation is the most frequent technique for molar evacuation, hysterectomy is a viable option in older patients who do not wish to preserve fertility. Despite advances in chemotherapy regimens for treating malignant gestational trophoblastic neoplasia, hysterectomy and other extirpative procedures continue to play a role in the management of patients with both low-risk and high-risk gestational trophoblastic neoplasia. Primary hysterectomy can reduce the amount of chemotherapy required to treat low-risk disease, whereas surgical resections, including hysterectomy, pulmonary resections, and other extirpative procedures, can be invaluable for treating highly selected patients with persistent, drug-resistant disease. Radiation therapy is also often incorporated into the multimodality therapy of patients with high-risk metastatic disease. This review discusses the indications for and the role of surgical interventions during the management of women with hydatidiform moles and malignant gestational trophoblastic neoplasia and reviews the use of radiation therapy in the treatment of women with malignant gestational trophoblastic neoplasia.
- 23 May 2010
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 15 (6) , 593-600
The Role of Surgery and Radiation Therapy in the Management of Gestational Trophoblastic Disease
Learning Objectives: After completing this course, the reader will be able to: Describe the indications for surgical intervention in the management of patients with hydatidiform moles and malignant GTN in order to choose patients most likely to benefit from these interventions.Discuss the use of radiation in the management of patients with malignant GTN and consider its use as an adjunct to chemotherapy or surgery. CME This article is available for continuing medical education credit at CME.TheOncologist.com The primary management of hydatidiform moles remains surgical evacuation followed by human chorionic gonadotropin level monitoring. Although suction dilatation and evacuation is the most frequent technique for molar evacuation, hysterectomy is a viable option in older patients who do not wish to preserve fertility. Despite advances in chemotherapy regimens for treating malignant gestational trophoblastic neoplasia, hysterectomy and other extirpative procedures continue to play a role in the management of patients with both low-risk and high-risk gestational trophoblastic neoplasia. Primary hysterectomy can reduce the amount of chemotherapy required to treat low-risk disease, whereas surgical resections, including hysterectomy, pulmonary resections, and other extirpative procedures, can be invaluable for treating highly selected patients with persistent, drug-resistant disease. Radiation therapy is also often incorporated into the multimodality therapy of patients with high-risk metastatic disease. This review discusses the indications for and the role of surgical interventions during the management of women with hydatidiform moles and malignant gestational trophoblastic neoplasia and reviews the use of radiation therapy in the treatment of women with malignant gestational trophoblastic neoplasia.
- 1 January 2007
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 17 (1) , 298-303
Comparison of gracilis and rectus abdominis myocutaneous flap neovaginal reconstruction performed during radical pelvic surgery: flap-specific morbidity
- 1 January 2007
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 17 (1) , 298-303
Comparison of gracilis and rectus abdominis myocutaneous flap neovaginal reconstruction performed during radical pelvic surgery: flap-specific morbidity